Association of Female Genital Schistosomiasis With the Cervicovaginal Microbiota and Sexually Transmitted Infections in Zambian Women

Amy S. Sturt,1,9 Emily L. Webb,2,6 Lisa Himschoot,4 Comfort R. Phiri,1 Joyce Mapani,2 Maina Mudendo,3 Eyrun F. Kjetland,7 Tobias Mweene,4 Bruno Levecke,6 Govert J. van Dam,4 Paul L. A. M. Cortijs,6 Helen Ayles,1,4 Richard J. Hayes,5 Lisette van Lieshout,9 Isaiah Hansingo,3 Suzanna C. Francis,2 Piet Cools,3,8 and Amaya L. Bustinduy1

1Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK; 2MRC International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine, London, UK; 3Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Gent University, Ghent, Belgium; 4Zambart, Lusaka, Zambia; 5Department of Obstetrics and Gynecology, Livingstone Central Hospital, Livingstone, Zambia; 6Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway; 7University of KwaZulu-Natal, Durban, South Africa; 8Department of Virology, Parasitology, and Immunology, Gent University, Merelbeke, Belgium; 9Department of Parasitology, Leiden University Medical Center, Leiden, the Netherlands, and 10Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands

Background. The cervicovaginal microbiota, including sexually transmitted infections (STIs), have not been well described in female genital schistosomiasis (FGS).

Methods. Women (aged 18–31, sexually active, nonpregnant) were invited to participate at the final follow-up of the HPTN 071 (PopART) Population Cohort in January–August 2018. We measured key species of the cervicovaginal microbiota (Lactobacillus crispatus, L. iners, Gardnerella vaginalis, Atopobium vaginae, and Candida) and STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium) using quantitative PCR (qPCR). We evaluated associations of the microbiota and STI presence and concentration with FGS (qPCR-detected Schistosoma DNA in any of 3 genital specimens).

Results. The presence and concentration of key cervicovaginal species did not differ between participants with (n = 30) or without FGS (n = 158). A higher proportion of participants with FGS had T. vaginalis compared with FGS-negative women (P = .08), with further analysis showing that T. vaginalis was more prevalent among women with ≥2 Schistosoma qPCR-positive genital specimens (50.0%, 8/16) than among FGS-negative women (21.5%, 34/158; P = .01).

Conclusions. We found weak evidence of an association between the presence of T. vaginalis and FGS, with a stronger association in women with a higher-burden FGS infection. Additional research is needed on potential between-parasite interactions, especially regarding HIV-1 vulnerability.

Keywords. cervicovaginal microbiota; female genital schistosomiasis; Schistosoma haematobium; sexually transmitted infection.

Female genital schistosomiasis (FGS) is caused when eggs from the waterborne parasite S. haematobium are entrapped in genital tissue [1]. FGS is prevalent in Sub-Saharan Africa and is associated with adverse reproductive outcomes, including ectopic pregnancy, infertility, and prevalent HIV-1 [1, 2]. The cervicovaginal environment has been described as “optimal” when it is dominated by lactic acid–producing lactobacilli, commensal microorganisms that adhere to an intact vaginal squamous epithelium [3, 4], protecting against pathogens by acidifying the vagina and producing antimicrobial substances such as bacteriocins [3]. Bacterial vaginosis (BV) and vulvovaginal candidiasis are examples of “nonoptimal” microbiota. BV is prevalent in women in Sub-Saharan Africa [5, 6] and is characterized by a shift from lactobacilli dominance to an increase in anaerobic species or yeast [4]. BV has important sexual and reproductive health consequences, including increased risk of pelvic inflammatory disease [5]. Additionally, BV has been associated with adverse pregnancy outcomes such as preterm delivery [5, 7], a leading cause of under-5 mortality in Sub-Saharan Africa [8]. BV is also strongly associated with HIV-1 acquisition and other sexually transmitted pathogens infecting the genital tract [5, 9, 10]. Studies employing 16S rRNA sequencing to evaluate the cervicovaginal microbiota suggest that high-intensity urinary S. haematobium infection, in the absence of investigation for genital involvement, may alter cervicovaginal microbiota diversity [11]. However, the relationship between cervicovaginal microbiota and FGS is not well characterized.

Prevalent sexually transmitted infections (STIs) have been reported in women with [12] or in populations endemic for [13,
urinary schistosomiasis. However, evaluation of genital involvement (FGS) in studies of urinary *S. haematobium* and STI co-infection is not universally performed or reported [12–14]. The biopsy prevalence of FGS in participants with urinary *S. haematobium* infection ranges from 23.0% to 75.0% ([15, 16]), making the assumption of genital involvement (FGS) in urinary *S. haematobium* infection tenuous. A reference standard diagnostic does not exist for FGS. Thus, an FGS evaluation is often based on a combination of diagnostic tests including circulating anodic antigen (CAA), urine microscopy, colposcopy, tissue-based diagnostics (biopsy, Papanicolaou smear, wet prep), and polymerase chain reaction (PCR) [17–19]. Where an FGS evaluation has been performed, studies reporting PCR-defined FGS have either not investigated or reported STI prevalence [20–22] or STI prevalence has been correlated with visual FGS findings [23]. In this cross-sectional study, we utilized PCR to detect *Schistosoma* DNA in the female genital tract and evaluated the association of PCR-defined FGS with the concentration and presence of key markers of the cervicovaginal microbiota, including STI.

**METHODS**

**Study Setting and Participants**

The cross-sectional bilharzia and HIV (BILHIV) study [18] was nested in HPTN 071 (PopART), a cluster randomized trial to measure the impact of an HIV-1 combination prevention package [24]. In HPTN 071 (PopART), HIV-1 incidence was measured in a population cohort at baseline and 12, 24, and 36 months [24]. Between January and August 2018, after the 36-month HPTN 071 (PopART) visit, community workers made home visits to women expressing interest in the BILHIV study [18]. Eligible women were aged 18–31 years, not pregnant, sexually active, and resident in 1 of 2 urban communities that participated in HPTN 071 (PopART) in Livingstone, Zambia.

**Home and Clinic-Based Sample Collection**

The home visit included written informed consent, a questionnaire, genital self-sampling (cervical and vaginal), and urine specimen collection, as previously described [18]. Enrolled women not currently menstruating were invited to attend Livingstone Central Hospital cervical cancer clinic, where midwives performed cervicovaginal lavage (CVL). After speculation insertion, a bulb syringe was used to flush normal saline (10 mL) across the cervix and vaginal walls for 1 minute. CVL fluid was collected from the posterior fornices (Supplementary Data). CVL and vaginal and cervical swab specimens were used for quantitative PCR (qPCR) detection of *Schistosoma*; cervical swabs were used for characterization of the microbiota and STI by qPCR; urine was used for detection of CAA and *S. haematobium* eggs by microscopy.

Cervicovaginal images were captured with a portable colposcope (MobileODT, Tel Aviv, Israel) and were evaluated (by E.F.K.) for any of the 4 recognized FGS cervicovaginal manifestations: grainy sandy patches, homogenous yellow sandy patches, rubbery papules, and abnormal blood vessels [25]. Women with at least 1 of these manifestations [25] or with any positive urine or genital *Schistosoma* diagnostic were treated free of charge with 40 mg/kg of praziquantel. Testing for STI was not performed at the point of care, and participants with suspected STI were offered syndromic management, as per local guidelines [26].

**HIV-1**

Laboratory-based fourth-generation HIV-1 testing (Abbott Architect HIV Ag/Ab Combo Assay) was performed for HPTN 071 (PopART) Population Cohort participants at each study visit [24].

**Urine Microscopy and Circulating Anodic Antigen**

Urine was centrifuged and examined by microscopy for *S. haematobium* eggs. The participant was considered positive if a pellet contained at least 1 *S. haematobium* egg [18]. A lateral flow assay utilizing up-converting reporter particles for the quantification of CAA was performed on urine samples, as previously described [18, 27]. Analyzing the equivalent of 417 µL of urine (wet reagent, UCAAh/T417), a test result indicating a CAA value >0.6 pg/mL was considered positive [28].

**qPCR for Detection of Schistosoma DNA**

Detection of the *Schistosoma*-specific internal-transcribed-spacer-2 (ITS2) target by qPCR was performed at LUMC, as previously described (Supplementary Data) [18, 29]. DNA extraction of 200 µL of CVL or cervical or vaginal swab fluid was done with QIAamp spin columns (QIAGEN Benelux, Venlo, the Netherlands) according to manufacturer’s guidelines. The qPCR output was reported in cycle threshold values (Ct values), and parasite DNA loads were categorized by the following prespecified values: high (Ct < 30), moderate (30 ≤ Ct < 35), low (35 ≤ Ct < 50), and negative (no amplification) [30].

**Cervicovaginal Microbiota Characterization and STI Detection**

We quantified *Lactobacillus crispatus* as a key marker of vaginal health. Additionally, we characterized markers of a “nonoptimal” cervicovaginal microbiota (*Gardnerella vaginalis* and *Atopobium vaginae*), as well as *L. iners* (an enigmatic and highly prevalent lactobacillus), *Candida spp.* and STI (*Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium*, and *Trichomonas vaginalis*). STI were quantified by qPCR using the S-DiaCTNG (for *C. trachomatis* and *N. gonorrhoea*) and S-DiaMGTV kits (for *M. genitalium* and *T. vaginalis*; Diagnode Diagnostics, Seraing, Belgium) on DNA from cervical swabs at Ghent.

Downloaded from https://academic.oup.com/ofid/article/8/9/ofab438/6356223 by guest on 10 October 2021
University (Ghent, Belgium) according to the manufacturer's instructions. Quantification of *A. vaginae*, *G. vaginalis*, *L. crispatus*, *L. iners*, and *Candida* species was performed in the Laboratory Bacteriology Research, Ghent, using LightCycler480, version 1.5 (Roche, Basel, Switzerland) (Supplementary Data). The concentration of each species was expressed as genome-equivalents per mL (ge/mL) [31].

**FGS Definitions**

In this study, we employed various diagnostic tests to evaluate urinary schistosome infection (CAA and urine microscopy) and FGS (portable colposcopy and *Schistosoma* DNA on CVL and genital swabs). As previously described [32], participants were grouped by diagnostic test results into 3 mutually exclusive categories: FGS, at least 1 positive *Schistosoma* qPCR on a genital specimen (cervical swab, vaginal swab, and/or CVL); FGS negative, negative results on all diagnostic methods; probable FGS, genital *Schistosoma* qPCRs negative but urinary schistosomiasis positive (as defined above), in combination with 1 of 4 clinical findings suggestive of FGS on any colposcope-obtained photograph [25].

**Patient Consent**

The study was approved by the University of Zambia Biomedical Research Ethics Committee (011-08-17), the Zambia National Health Research Authority, and the London School of Hygiene and Tropical Medicine Ethics Committee (14506). Permission to conduct the study was given by Livingstone District Health Office and the Livingstone Central Hospital superintendent. Participants provided written informed consent.

**Statistical Methods**

All participants with FGS (n = 30) and all participants with probable FGS (n = 25) were selected for characterization of the cervicovaginal microbiota and STI by qPCR on cervical swabs. Three FGS-negative participants were selected for every FGS and probable FGS participant using a random number generator. The FGS-negative participants were frequency-matched by age to participants with FGS (age groups 18–19, 20–21, 22–23, 24–25, 26–27, 28–29, 30–31).

Participant characteristics were summarized by median and interquartile range (IQR) for continuous variables and by frequency and percentage for categorical variables. Differences in characteristics between FGS categories were evaluated using the Fisher exact or chi-square test. For cervicovaginal microbiota and STI species with at least 20% of sample results detectable by qPCR (ie, ≥20% prevalence), *P* values for comparison of presence, median (IQR), and log₁₀ concentration mean between FGS and FGS-negative groups were calculated using the chi-square test, rank-sum test, and *t* test, respectively. For species with <20% prevalence, species presence was compared between FGS groups using the Fisher exact test. To enable investigation of potential confounding, concentrations of cervicovaginal microbiota with ≥20% prevalence were log-transformed to normalize their distribution, and linear regression was used to evaluate the association between FGS and mean log-concentration of each organism (ge/mL) in univariable and multivariable analysis. We developed a causal framework (Supplementary Figure 1) to inform our minimal adjustment set and adjusted for age, education, and community of residence. For all species, logistic regression was used to calculate the crude and adjusted odds ratio (OR) for presence vs absence by FGS group; due to the relatively low number of participants with detectable concentrations, logistic regression analyses only adjusted for age. Given the exploratory nature of this work, we did not correct for multiple comparisons.

Our primary analysis focused on the detection of *Schistosoma* DNA in the genital tract (FGS vs FGS negative). A secondary analysis compared the FGS and probable FGS groups with the FGS-negative participants. To evaluate the possible association between FGS burden and changes in presence and concentration of cervicovaginal key species, 2 ad hoc analyses were performed: (1) participants with ≥2 genital samples with detectable *Schistosoma* DNA were compared with the FGS-negative group, (2) participants with a moderate/high genital *Schistosoma* DNA concentration (Ci < 35 in at least 1 of 3 samples) were compared with the FGS-negative group. Data were analyzed using STATA 15.1 (Stata Corporation, College Station, TX, USA).

**RESULTS**

A total of 603 eligible women were enrolled in the BILHIV study, and 213 (35.3%) were included in the present study (Supplementary Figure 1). Of those included, 14.1% (30/213) had FGS, defined by a positive genital *Schistosoma* qPCR from any of the following sites: 9.4% (20/213) cervical swab, 7.0% (15/213) vaginal swab, and 6.6% (14/211) CVL. In participants with FGS, portable colposcopy revealed sandy patches in 20% (6/30), abnormal blood vessels in 20% (6/30), and no clinical signs of FGS in 50% (15/30). Two women with FGS did not present to the clinic for portable colposcopy, and 1 had uninterpretable images. Of participants with FGS, 53.3% (16/30) had *Schistosoma* qPCR detected from multiple sites, and 53.3% (16/30) had moderate/high genital *Schistosoma* DNA loads; these groups overlapped by 12 participants. Twenty-five women had probable FGS, and 74.2% (158/262) of the women who were negative on all diagnostic tests were randomly selected for inclusion in this study. Consistent with the FGS definitions, portable colposcopy in 100.0% (25/25) of the participants with probable FGS showed FGS-associated cervicovaginal manifestations. In the majority of participants with probable FGS, portable colposcopy showed sandy patches (76.0%, 19/25), with 24% (6/25) of participants having abnormal blood vessels.
Baseline Characteristics
The majority of the participants were married/cohabiting, had received some secondary education, and were using hormonal contraception (Table 1). At the conclusion of HPTN 071 (PopART), HIV-1 prevalence was 17.4% (37/213) among the women included in this study, and one-third had at least 1 STI (Table 1). Urinary schistosomiasis infection, defined as either a positive urine microscopy (11.7%, 25/213) or positive CAA (20.7%, 44/213), was reported in 21.6% (46/213) of participants. There were differences between the 3 categories of FGS status for age (P = .002), marital status (P = .04), education (P = .06), and employment (P = .04), with participants in the probable FGS group being more likely to be older, employed, and married than FGS and FGS-negative participants. There was strong evidence of a difference in community of residence by FGS status (P < .001), with participants with FGS and probable FGS more likely to live in Community A than participants in the FGS-negative group (Table 1). Other characteristics were similar by FGS status.

Primary Comparison: FGS vs FGS Negative
Concentrations of evaluated species are shown in Figure 1. Compared with FGS-negative women, there was no evidence of a difference in the presence or concentration of cervicovaginal L. crispatus, L. iners, A. vaginae, G. vaginalis, or C. albicans in participants with FGS (Table 2). A higher proportion of participants with FGS had T. vaginalis present, although there was not strong evidence of an association (OR, 2.11; 95% CI, 0.92–4.86; P = .08) (Supplementary Table 1). This result was similar after adjusting for age (Supplementary Table 1). Otherwise, compared with FGS-negative women, the presence and concentration of other STIs were similar in women with FGS (Table 2).

Combining the FGS and probable FGS groups, participants with FGS/probable FGS similarly had a higher prevalence of T. vaginalis compared with FGS-negative participants (P = .05) (Supplementary Table 2). Otherwise, compared with FGS-negative women, the presence and concentrations of cervicovaginal microbiota and the presence of STI were similar in women with FGS/probable FGS compared with FGS-negative participants (Supplementary Table 2).

Ad Hoc Analysis—Schistosoma DNA Concentration
In participants (n = 16) with FGS and a moderate/high genital Schistosoma DNA concentration (Schistosoma qPCR Ct < 35), the presence of T. vaginalis was higher than among the FGS-negative participants (P = .01) (Table 3). Women with FGS and a moderate/high Schistosoma DNA concentration (Ct < 35) had a higher mean concentration of G. vaginalis compared with FGS-negative women (P = .03) (Table 3).

Ad Hoc Analysis—Clinical Disease Burden
In an ad hoc analysis, participants (n = 16) with a higher FGS burden, defined as ≥2 Schistosoma qPCR–positive genital specimens, had higher prevalence of T. vaginalis compared with FGS-negative participants (P = .01) (Table 4). There was also evidence of a difference in the median concentration and the mean log-concentration of L. iners (both P = .03) compared with FGS-negative women, with lower levels among the higher-FGS burden group (Table 4).

DISCUSSION
In this study, we describe the association of FGS with the cervicovaginal microbiota, including lactobacilli, Candida spp., markers of a “nonoptimal” cervicovaginal environment, and STI. We did not find evidence that the presence or concentration of key cervicovaginal species was associated with FGS. While FGS was not associated with C. trachomatis, M. genitalium, or N. gonorrhoeae, there was weak evidence of an association of presence of T. vaginalis with FGS, which remained after adjusting for age. This association was also present when participants with FGS and probable FGS were combined and was strengthened in the ad hoc analyses of participants with higher-burden FGS.

We performed 2 ad hoc analyses. High-intensity S. haematobium infection, in the absence of evaluation for FGS, has been associated with higher cervicovaginal alpha diversity [11]. Thus, first we investigated whether Schistosoma DNA concentrations might be associated with the cervicovaginal microbiota in 16 participants with a higher FGS burden, indicated by moderate/high genital Schistosoma DNA concentrations. In this ad hoc analysis, we found that the G. vaginalis log-concentration mean was higher in women with a higher FGS burden. Participants underwent CVL when they were not menstruating, and we have previously described that 66.2% (139/210) of women in this cohort had detectable CVL hemoglobin. Iron sources, like hemoglobin, are often required for bacterial growth [33]. G. vaginalis is well adapted to harvest iron from the environment [34], and higher concentrations of G. vaginalis coincide with menses [33]. Cervical tissue in women with FGS is more vascularized than non-egg-containing tissue, and thus the abnormal cervical vessels and contact bleeding seen in clinical FGS provide a plausible link to increased concentrations of G. vaginalis in high-burden FGS [35].

In a second ad hoc analysis, we examined participants with multiple qPCR-positive genital specimens as a potential proxy marker of high-burden FGS and found that reduced a L. iners concentration (median and log mean) was associated with high-burden FGS. The cervicovaginal microbiota was characterized with 16S rRNA sequencing in Tanzanian women with S. haematobium infection (n = 16). Although power was limited, women with high-intensity S. haematobium infection had reduced abundance of L. iners compared with women with low-intensity infection, albeit without evidence of a difference (P = .39) [11]. Further research is needed to evaluate the
### Table 1. Baseline Characteristics of the Study Population (n = 213) by FGS Status

| Participant Characteristics | FGS Negative, No. (%) (n = 158) | Probable FGS, No. (%) (n = 25) | FGS, No. (%) (n = 30) | P Valuea |
|----------------------------|---------------------------------|-------------------------------|----------------------|---------|
| **Age, median (IQR), y** | 23 (22–24) | 27 (23–31) | 22 (21–24) | .002b |
| **Marital status** | | | | |
| Single | 72 (45.6) | 4 (16.0) | 13 (43.3) | .04 |
| Married or cohabitating | 81 (51.3) | 20 (80.0) | 17 (56.7) | |
| Divorced or separated | 5 (3.2) | 1 (4.0) | 0 (0.0) | |
| **Education (highest level)** | | | | |
| None or any primary school | 35 (22.2) | 12 (48.0) | 10 (33.3) | .06 |
| Any secondary school | 111 (70.3) | 5 (20.0) | 8 (26.7) | |
| Trade, degree or higher | 12 (7.6) | 0 (0.0) | 1 (3.3) | |
| **District** | | | | |
| Community A | 66 (41.8) | 20 (80.0) | 22 (73.3) | <.01 |
| Community B | 92 (58.2) | 5 (20.0) | 8 (26.7) | |
| **Household members** | | | | |
| 1–3 | 51 (32.3) | 4 (16.0) | 12 (40.0) | .3 |
| 4–5 | 61 (38.6) | 13 (52.0) | 8 (26.7) | |
| 6+ | 46 (29.1) | 8 (32.0) | 10 (33.3) | |
| **Employment status** | | | | |
| Not working | 26 (16.6) | 2 (8.0) | 3 (10.0) | .5 |
| Working | 131 (83.4) | 23 (92.0) | 27 (90.0) | |
| **Sexual behavior characteristics** | | | | |
| Age at sexual debut, y | 8–16 | 64 (40.5) | 11 (44.0) | 17 (56.7) | .4 |
| 17–19 | 74 (46.8) | 13 (52.0) | 10 (33.3) | |
| 20–24 | 20 (12.7) | 1 (4.0) | 3 (10.0) | |
| **Lifetime sexual partners** | | | | |
| 1 | 57 (36.1) | 8 (32.0) | 5 (16.7) | .3 |
| 2 | 36 (22.8) | 6 (24.0) | 9 (30.0) | |
| 3 | 23 (14.6) | 6 (24.0) | 8 (26.7) | |
| 4+ | 42 (26.6) | 5 (20.0) | 8 (26.7) | |
| **Currently sexually activec,d** | | | | |
| No | 26 (16.6) | 2 (8.0) | 3 (10.0) | .5 |
| Yes | 131 (83.4) | 23 (92.0) | 27 (90.0) | |
| **Condom use with last sex**e | | | | |
| No | 120 (76.9) | 16 (66.7) | 22 (73.3) | .6f |
| Yes | 36 (23.1) | 8 (33.3) | 8 (26.7) | |
| **HIV-1 status** | | | | |
| Not detected | 132 (83.5) | 20 (80.0) | 24 (80.0) | .8 |
| Detected | 26 (16.5) | 5 (20.0) | 6 (20.0) | |
| **Any STI**g | | | | |
| Not detected | 106 (67.1) | 14 (56.0) | 18 (60.0) | .5 |
| Detected | 100 (63.3) | 11 (44.0) | 12 (40.0) | |
| **Contraceptive use** | | | | |
| Condoms | No | 132 (83.5) | 20 (80.0) | 26 (86.7) | .8 |
| Yes | 26 (16.5) | 5 (20.0) | 4 (13.3) | |
| OCP | No | 148 (93.7) | 22 (88.0) | 29 (96.7) | .5 |
| Yes | 10 (6.3) | 3 (12.0) | 1 (3.3) | |
| Injectable | No | 82 (51.9) | 13 (52.0) | 15 (50.0) | 1.0f |
| Yes | 76 (48.1) | 12 (48.0) | 15 (50.0) | |
| Implant | No | 144 (91.1) | 23 (92.0) | 28 (93.3) | 1.0 |
| Yes | 14 (8.9) | 2 (8.0) | 2 (6.7) | |
| **Any hormonal contraception**h | | | | |
| No | 58 (36.7) | 8 (32.0) | 10 (35.7) | .9f |
| Yes | 100 (63.3) | 17 (68.0) | 18 (64.3) | |
| **Schistosomiasis-related factors** | | | | |
| Urine microscopy | Not detected | 158 (100.0) | 19 (76.0) | 11 (36.7) | <.001i |
| Detected | 0 (0.0) | 6 (24.0) | 19 (63.3) | |
| Urine CAA | Negative | 158 (100.0) | 0 (0.0) | 11 (36.7) | <.001i |
| Positive | 0 (0.0) | 25 (100.0) | 19 (63.3) | |

Abbreviations: CAA, circulating anodic antigen; FGS, female genital schistosomiasis; IQR, interquartile range; OCP, oral contraceptive pill; STI, sexually transmitted infection.

aFisher’s exact P value unless otherwise indicated.

bKruskal-Wallis P value.
cAny sexual activity in the last 6 months.
dParticipants who responded with “no answer” (n = 1) are not shown in the table.
eParticipants who responded with “no answer” (n = 3) are not shown in the table.
fChi-square P value.
gAny STI defined as the presence of at least 1 of *N. gonorrhoeae*, *C. trachomatis*, *M. genitalium*, or *T. vaginalis*.
hAny hormonal contraception is defined as use of injectable agents, implants, or oral contraceptive pills.
iPart of the definition for FGS categories.
relationship between the presence and concentration of *L. iners* in FGS.

In both ad hoc analyses, we found that presence of *T. vaginalis* was higher among the participants with a higher FGS burden. Our finding supports results from a small South African study (*n* = 45) that reported an association between FGS (diagnosed by identification of sandy patches on colposcopy) and presence of *T. vaginalis* in young women (ages 15–23) [36]. Acquisition of *T. vaginalis* and *S. haematobium* may share common risk factors, like age and socioeconomic status [18]. We have previously described higher FGS prevalence among younger age groups [18]. Epidemiologic data from Zambian adolescents, sex workers, and pregnant women (aged 13–45 years) describe a *T. vaginalis* prevalence between 24.6% and 33.2% [37], consistent with the prevalence in our population (24.9%). While *S. haematobium* is geographically restricted to Africa and the Middle East, it is associated with poverty [38] and is acquired through contact with cercaria-infested fresh water [1]. *T. vaginalis* is primarily sexually transmitted, is prevalent worldwide, with the highest prevalence in

Table 2. Presence and Concentration of Vaginal Lactobacilli, Other Key Microbiota, and Sexually Transmitted Infection, Overall and by FGS Status

| Organism                  | Presence | All Participants (n = 213) | FGS Negative (n = 158) | FGS (n = 30) | P Value*
|---------------------------|----------|---------------------------|------------------------|--------------|----------
| *L. crispatus*            | Presence | 69 (32.4)                 | 49 (31.0)              | 13 (43.3)    | .19      |
|                           | Median (IQR) | 8.7×10^6 (2.6×10^5–4.2×10^6) | 1.1×10^7 (2.6×10^5–7.0×10^6) | 7.5×10^6 (1.9×10^5–2.7×10^7) | .20      |
|                           | Log-concentration mean | 16.01 | 16.38 | 14.82 | .19      |
| *L. iners*                | Presence | 156 (73.2)                | 113 (71.5)             | 24 (80.0)    | .34      |
|                           | Median (IQR) | 2.7×10^9 (8.8×10^7–1.5×10^9) | 2.8×10^9 (3.9×10^7–1.6×10^9) | 1.7×10^9 (1.6×10^7–1.0×10^9) | .39      |
|                           | Log-concentration mean | 18.91 | 18.98 | 18.36 | .33      |
| *G. vaginalis*            | Presence | 156 (73.2)                | 115 (72.8)             | 23 (76.7)    | .66      |
|                           | Median (IQR) | 7.7×10^10 (8.3×10^9–5.2×10^10) | 8.1×10^9 (7.7×10^9–4.8×10^9) | 3.8×10^9 (6.8×10^8–6.4×10^9) | .93      |
|                           | Log-concentration mean | 15.85 | 15.74 | 15.91 | .79      |
| *A. vaginae*              | Presence | 152 (71.4)                | 112 (70.9)             | 19 (63.3)    | .41      |
|                           | Median (IQR) | 5.8×10^10 (8.2×10^9–2.1×10^10) | 5.8×10^10 (8.7×10^9–2.0×10^10) | 3.0×10^9 (1.06×10^10–2.8×10^10) | .83      |
|                           | Log-concentration mean | 17.31 | 17.33 | 17.06 | .66      |
| *T. vaginalis*            | Presence | 53 (24.9)                 | 34 (21.5)              | 11 (38.7)    | .08      |
|                           | Median (IQR) | 4.2×10^7 (173.0–2.3×10^9) | 1.7×10^7 (56.9–6.3×10^6) | 1.0×10^6 (5030.0–4.5×10^6) | .53      |
|                           | Log-concentration mean | 10.39 | 10.88 | 10.19 | .69      |

Vaginal microbiota with prevalence <20%

| Organism                  | Presence | All Participants (n = 213) | FGS Negative (n = 158) | FGS (n = 30) | P Value*
|---------------------------|----------|---------------------------|------------------------|--------------|----------
| *N. gonorrhoeae*          | Presence | 13 (6.1)                  | 12 (7.6)               | 0 (0.0)      | .22      |
| *C. trachomatis*          | Presence | 17 (8.0)                  | 13 (8.2)               | 3 (10.0)     | .72      |
| *M. genitalium*           | Presence | 8 (3.6)                   | 7 (4.4)                | 0 (0.0)      | .60      |
| *C. albicans*             | Presence | 12 (5.63)                 | 8 (5.1)                | 2 (6.7)      | .66      |

Abbreviations: FGS, female genital schistosomiasis; IQR, interquartile range.

*Concentrations are expressed in genome equivalents/mL.

*For species with >20% prevalence, P values for presence, median (IQR), and log-concentration mean are from the chi-square test, rank-sum test, and t-test, respectively. For species with <20% prevalence, P values for presence are from the Fisher exact test.
### Table 3. Ad Hoc Analysis of the Presence and Concentration of Vaginal Lactobacilli, Other Cervicovaginal Microbiota, and Sexually Transmitted Infection in Participants With a Moderate to High Concentration of Schistosoma DNA (Ct < 35) Compared With FGS-Negative Participants

| Organism     | No. (%) and Concentration* | FGS Negative (n = 158) | FGS With Ct < 35 (n = 16) | P Valueb |
|--------------|----------------------------|------------------------|---------------------------|----------|
| *L. crispatus* | Presence                  | 49 (31.0)              | 6 (37.5)                  | .60      |
|              | Median (IQR)              | 1.1 × 10⁷ (2.6 × 10⁶–7.0 × 10⁸) | 1.2 × 10⁶ (3.0 × 10⁵–2.0 × 10⁷) | .28      |
|              | Log-concentration mean    | 16.38                  | 14.27                     | .19      |
| *L. iners*   | Presence                  | 113 (71.5)             | 11 (68.75)                | .82      |
|              | Median (IQR)              | 2.8 × 10⁷ (3.9 × 10⁶–1.6 × 10⁹) | 7.5 × 10⁷ (3.6 × 10⁶–7.5 × 10⁸) | .30      |
|              | Log-concentration mean    | 18.98                  | 17.86                     | .21      |
| *G. vaginalis* | Presence                | 115 (72.8)             | 13 (81.3)                 | .46      |
|              | Median (IQR)              | 8.1 × 10⁷ (2.7 × 10⁶–4.8 × 10⁸) | 1.5 × 10⁷ (3.8 × 10⁶–3.1 × 10⁸) | .11      |
|              | Log-concentration mean    | 15.74                  | 17.45                     | .03      |
| *A. vaginae* | Presence                  | 112 (70.9)             | 13 (81.3)                 | .38      |
|              | Median (IQR)              | 5.8 × 10⁷ (8.7 × 10⁶–2.0 × 10⁹) | 1.6 × 10⁸ (1.6 × 10⁷–2.8 × 10⁸) | .70      |
|              | Log-concentration mean    | 17.33                  | 17.38                     | .95      |
| *T. vaginalis* | Presence               | 34 (21.5)              | 8 (50.0)                  | .01      |
|              | Median (IQR)              | 1.7 × 10⁷ (5.6 × 10⁶–6.3 × 10⁸) | 8085.0 (5210.0–1.0 × 10⁸) | .56      |
|              | Log-concentration mean    | 10.88                  | 10.09                     | .70      |

Vaginal microbiota with prevalence <20%

| Organism     | No. (%) and Concentration* | FGS Negative (n = 158) | FGS With Ct < 35 (n = 16) | P Valueb |
|--------------|----------------------------|------------------------|---------------------------|----------|
| *N. gonorrhoeae* | Presence               | 12 (7.6)               | 0 (0.0)                   | .61      |
| *C. trachomatis* | Presence            | 13 (8.2)               | 2 (12.5)                  | .63      |
| *M. genitalium* | Presence            | 7 (4.4)                | 0 (0.0)                   | 1.0      |
| *C. albicans*  | Presence                | 8 (5.1)                | 2 (12.5)                  | .23      |

Abbreviations: Ct, cycle threshold; FGS, female genital schistosomiasis; IQR, interquartile range.

*Concentrations are expressed in genome equivalents/mL.

bFor species with >20% prevalence, P values for presence, median (IQR), and log-concentration mean are from the chi-square test, rank-sum test, and t test, respectively. For species with <20% prevalence, P values for presence are from the Fisher exact test.

### Table 4. Ad Hoc Analysis of the Presence and Concentration of Vaginal Lactobacilli, Cervicovaginal Microbiota, and Sexually Transmitted Infection in Participants With Schistosoma DNA Detected in ≥2 Genital Specimens Compared With FGS-Negative Participants

| Organism     | No. (%) and Concentration* | FGS Negative (n = 158) | ≥2 PCR FGS (n = 16) | P Valueb |
|--------------|----------------------------|------------------------|---------------------|----------|
| *L. crispatus* | Presence                  | 49 (31.0)              | 7 (43.8)            | .30      |
|              | Median (IQR)              | 1.1 × 10⁷ (2.6 × 10⁶–7.0 × 10⁸) | 1.9 × 10⁸ (7.7 × 10⁶–2.7 × 10⁸) | .32      |
|              | Log-concentration mean    | 16.38                  | 14.90               | .34      |
| *L. iners*   | Presence                  | 113 (71.5)             | 10 (62.5)           | .45      |
|              | Median (IQR)              | 2.8 × 10⁷ (3.9 × 10⁶–1.6 × 10⁹) | 5.1 × 10⁷ (9.0 × 10⁶–1.1 × 10⁸) | .03      |
|              | Log-concentration mean    | 18.98                  | 17.00               | .03      |
| *G. vaginalis* | Presence                | 115 (72.8)             | 14 (87.5)           | .20      |
|              | Median (IQR)              | 8.1 × 10⁷ (2.7 × 10⁶–4.8 × 10⁸) | 1.6 × 10⁷ (1.1 × 10⁶–3.6 × 10⁸) | .29      |
|              | Log-concentration mean    | 15.74                  | 16.85               | .16      |
| *A. vaginae* | Presence                  | 112 (70.9)             | 11 (68.8)           | .86      |
|              | Median (IQR)              | 5.8 × 10⁷ (8.7 × 10⁶–2.0 × 10⁹) | 1.6 × 10⁸ (2.7 × 10⁷–3.2 × 10⁸) | .33      |
|              | Log-concentration mean    | 17.33                  | 18.04               | .36      |
| *T. vaginalis* | Presence               | 34 (21.5)              | 8 (50.0)            | .01      |
|              | Median (IQR)              | 1.7 × 10⁷ (5.6 × 10⁶–6.3 × 10⁸) | 5680.0 (29675.0–1.0 × 10⁸) | .56      |
|              | Log-concentration mean    | 10.88                  | 9.71                | .56      |

Vaginal microbiota with prevalence <20%

| Organism     | No. (%) and Concentration* | FGS Negative (n = 158) | ≥2 PCR FGS (n = 16) | P Valueb |
|--------------|----------------------------|------------------------|---------------------|----------|
| *N. gonorrhoeae* | Presence               | 12 (7.6)               | 0 (0.0)            | .61      |
| *C. trachomatis* | Presence            | 13 (8.2)               | 2 (12.5)           | .63      |
| *M. genitalium* | Presence            | 7 (4.4)                | 0 (0.0)            | 1.0      |
| *C. albicans*  | Presence                | 8 (5.1)                | 1 (6.3)            | .59      |

Abbreviations: FGS, female genital schistosomiasis; IQR, interquartile range; PCR, polymerase chain reaction.

*Concentrations are expressed in genome equivalents/mL.

bFor species with >20% prevalence, P values for presence, median (IQR), and log-concentration mean are from the chi-square test, rank-sum test, and t test, respectively. For species with <20% prevalence, P values for presence are from the Fisher exact test.
women from low-income countries [39]. Both *S. haematobium* [40] and *T. vaginalis* infection [41, 42] have been reported as risk factors for HIV-1 acquisition, although these associations are not universally reported [43]. Additionally, *T. vaginalis* may influence HIV-1 transmission. Studies in women not uniformly receiving antiretroviral therapy (ART) with *T. vaginalis* show a decline in genital HIV-1 shedding after metronidazole therapy [44–46]. However, this decline in cervical HIV-1 shedding was not seen in a study of Kenyan women receiving ART [47]. The highest global *T. vaginalis* incidence rates have been reported in Africa [39]. Overlapping synergies between *T. vaginalis* and *S. haematobium* cervicovaginal pathogenesis may begin with, but are not limited to, disruption of the cervicovaginal epithelium [48]. Both parasites have been associated with characteristic cervicovaginal manifestations [17, 49], the "strawberry cervix" in *T. vaginalis* [49] and sandy patches, rubbery papules, and abnormal blood vessels in FGS [17]. Breaches in the cervicovaginal epithelium in *T. vaginalis* infection potentially represent one mechanism of HIV-1 vulnerability in what is likely a multifactorial cascade, including modulating the cervicovaginal immune environment [50–52], disabling innate immunity [51], and disrupting the local microbiota [52]. To disentangle the association between *S. haematobium*, *T. vaginalis*, and HIV-1, future studies using sensitive molecular methods for both parasites are needed. Additionally, macrophage polarization can be influenced by the local immune environment, schistosomes, and *T. vaginalis* [53, 54]. We have previously shown that, compared with FGS-negative women, high-burden FGS is associated with higher concentrations of cervicovaginal Th2 cytokines [32]. A mouse model of urogenital *S. haematobium* infection suggested that the Th2 immune environment may be associated with delayed pathogen clearance [55]. Thus, further research is needed regarding the interaction between the immune environment and macrophage phenotypes in FGS and their role in potentially influencing *T. vaginalis* persistence.

Our study is the first to evaluate the cervicovaginal microbiota and STI in FGS defined by qPCR. This is particularly relevant in a population of sexually active, nonpregnant women in the context of high HIV-1 prevalence. However, there are also some relevant limitations. FGS does not have an accepted diagnostic reference standard, and the sensitivity of cervicovaginal PCR for the detection of *Schistosoma* DNA is imperfect. Thus, studies using *Schistosoma* DNA to detect FGS may be subject to misclassification bias. To maximize sensitivity, we used the results of 3 genital specimens. This decision was supported by previous work showing a sensitivity of 80.0% (61.4%–92.3%) with a specificity of 100.0% (99.3%–100.0%) when vaginal and cervical swab PCR were compared with any positive genital PCR (CVL, cervical swab, or vaginal swab) as the reference standard [18]. The study was conducted in an urban location with relatively low *S. haematobium* prevalence; thus the numbers of FGS cases in the primary and ad hoc analyses were small, limiting precision in the effect sizes. This analysis also included multiple statistical comparisons; thus, we focused on the species that showed a consistent pattern of association across primary and ad hoc analyses, rather than overinterpreting significance testing for any 1 species in isolation. Evidence for these associations in the ad hoc analyses should be viewed as hypothesis-generating. Additionally, the cross-sectional study design limited our ability to assess FGS duration and the long-term impact on the prevalence and concentrations of key species or STIs. There were a number of behavioral and biological factors that were not measured in our study including tobacco use [56], viral STIs (human papillomavirus and herpes simplex virus–2) [56], and intravaginal cleansing practices [57]. As these factors may be associated with the cervicovaginal microbiota, we cannot exclude residual or unmeasured confounding. Genital swabs were self-collected by participants, raising the potential for false-negative genital swabs. In future work, β-globin PCR could be implemented as a positive control to confirm the presence of human DNA [18]. Lastly, we defined FGS by *Schistosoma* DNA detection on qPCR; however, we cannot exclude that cervicovaginal qPCR detected *S. haematobium* eggs from a sexual partner’s semen [18].

In conclusion, we report weak evidence of an association between presence of *T. vaginalis* and FGS, with a consistently stronger association in women with a higher burden FGS infection. Additional research is needed to understand the interactions between *S. haematobium* and *T. vaginalis*, especially regarding HIV-1 vulnerability.

**Acknowledgments**

We wish to acknowledge the participants for devoting their time and trust to this study. We would like to recognize the work performed by the BILHIV project supervisor Namakau Chola and the BILHIV community workers Ethel Mwansa, Mwiingana Lukonga, Ruth Mwanza, Mervis Kantukaleza, and Judith Lungu. Our work in Livingstone would not have been possible without support from Clement Mwakamui (Zambart). We gratefully acknowledge Eric A. T. Brien (LUMC) for performing the general *Schistosoma* PCR analysis and Claudia J. de Dood (LUMC) and Pysje T. Hoekstra (LUMC) for performing the CAA analysis.

**Financial support.** Dr. A. Bustinduy received funding from the Wellcome Trust (Award 205954/Z/17/Z). Dr. P. Cools received funding from the Research Foundation–Flanders (BOFSTG2019010101) and was financially supported by a Bill and Melinda Gates Foundation Project (OPP1120972). Dr. E. Webb and Professor R. Hayes received funding from MRC Grant Reference MR/K012126/1, and Dr. S. C. Francis received salary from MRC Grant Reference MR/N023692/1. These awards are jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and are also part of the EDCTP2 program supported by the European Union. HPTN 071 (PopART) was supported by the National Institute of Allergy and Infectious Diseases (NIAID) under Cooperative Agreements UM1-A1068619, UM1-A1066817, and UM1-A1068613, with funding from the US President’s Emergency Plan for AIDS Relief (PEPFAR); the International Initiative for Impact Evaluation with support from the Bill and Melinda Gates Foundation; the NIAID, the National Institute on Drug Abuse, and the National Institute of Mental Health, all part of the National Institutes of Health. Professor Eyrun

Dr. A. Bustinduy received funding from the Wellcome Trust (Award 205954/Z/17/Z). Dr. P. Cools received funding from the Research Foundation–Flanders (BOFSTG2019010101) and was financially supported by a Bill and Melinda Gates Foundation Project (OPP1120972). Dr. E. Webb and Professor R. Hayes received funding from MRC Grant Reference MR/K012126/1, and Dr. S. C. Francis received salary from MRC Grant Reference MR/N023692/1. These awards are jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and are also part of the EDCTP2 program supported by the European Union. HPTN 071 (PopART) was supported by the National Institute of Allergy and Infectious Diseases (NIAID) under Cooperative Agreements UM1-A1068619, UM1-A1066817, and UM1-A1068613, with funding from the US President’s Emergency Plan for AIDS Relief (PEPFAR); the International Initiative for Impact Evaluation with support from the Bill and Melinda Gates Foundation; the NIAID, the National Institute on Drug Abuse, and the National Institute of Mental Health, all part of the National Institutes of Health. Professor Eyrun
Kjetland was supported by South-Eastern Regional Health Authority, Norway, project #2016055. Bruno Levecke received funding from the Fund for Scientific Research-Flanders (Grant No. 1S5316N).

Potential conflicts of interest. The authors report no conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Author contributions. Amy S. Sturt—conceptualization, data curation, formal analysis, BLHIV project administration, visualization, original manuscript preparation, manuscript editing and revision. Emily L. Webb—conceptualization, data curation, formal analysis, supervision, visualization, original manuscript preparation, manuscript editing and revision. Lisa Himschoot—investigation, manuscript editing and revision. Lina Mudenda—investigation, writing–review and editing. Joyce Mapani—investigation, writing–review and editing. Erynn F. Kjetland—investigation, writing–review and editing. Tobias Mweene—investigation, writing–review and editing. Bruno Levecke—investigation, resources, writing–review and editing. Govert J. van Dam—investigation, writing–review and editing. Paul L. A. M. Corstjens—investigation, writing–review and editing. Lisette van Dam—investigation, writing–review and editing. Paul L. A. M. Corstjens—investigation, writing–review and editing. Govert J. van Dam—investigation, writing–review and editing. Paul L. A. M. Corstjens—investigation, writing–review and editing. Lisette van Dam—investigation, writing–review and editing. Paul L. A. M. Corstjens—investigation, writing–review and editing. Lisette van Dam—investigation, writing–review and editing. Paul L. A. M. Corstjens—investigation, writing–review and editing. Lisette van Dam—investigation, writing–review and editing. Emily L. Webb—conceptualization, data curation, formal analysis, supervision, BILHIV project administration, visualization, original manuscript preparation, manuscript editing and revision. Emily L. Webb—conceptualization, data curation, formal analysis, supervision, visualization, original manuscript preparation, manuscript editing and revision. Lisa Himschoot—investigation, manuscript editing and revision. Haita Hansinga—resources, supervision, writing–review and editing. Lisa van Lieshout—investigation, writing–review and editing. Sanna C. Francis—conceptualization, supervision, original manuscript preparation, manuscript editing and revision. Piit Cools—conceptualization, resources, investigation, original manuscript preparation, manuscript editing and revision. Amaya L. Bustinduy—conceptualization, funding acquisition, supervision, original manuscript preparation, manuscript editing and revision.

References
1. Sturt AS, Webb EL, Francis SC, et al. Beyond the barrier: female genital schistosomiasis as a potential risk factor for HIV-1 acquisition. Acta Trop 2020; 209:105524.
2. Kjetland EF, Ndhlovu PD, Gomo E, et al. Association between genital schistosomiasis and human immunodeficiency virus (HIV) infection among young women: a cross-sectional study in rural South Africa. PLoS One 2016; 11:e0160251.
3. Boris S, Barbès C. Role played by lactobacilli in controlling the population of vaginal pathogens. Microbes Infect 2000; 2:543–6.
4. McKinnon LR, Achilles SL, Bradshaw CS, et al. The evolving facets of bacterial vaginosis: implications for HIV transmission. AIDS Res Hum Retroviruses 2019; 35:219–28.
5. van de Wijgert J, Jespers V. The global health impact of vaginal dysbiosis. ResMicrobiol 2017; 168:859–64.
6. Torrone EA, Morrison CS, Chen PL, et al. STIMA Working Group. Prevalence of sexually transmitted infections and bacterial vaginosis among women in Sub-Saharan Africa: an individual participant data meta-analysis of 18 HIV prevention studies. PLoS Med 2015; 15:e1002511.
7. Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med 1995; 333:1737–42.
8. Liu L, Ora S, Hogan D, et al. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet 2015; 385:430–40.
9. Atashili J, Poole C, Ndumbe PM, et al. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 2008; 22:493–501.
10. Jespers V, Crucitti T, Menten J, et al. Vaginal Biomarkers Study Group. Prevalence and correlates of bacterial vaginosis in different sub-populations of women in Sub-Saharan Africa: a cross-sectional study. PLoS One 2014; 9:e89670.
11. Bullington JW, Lee MH, Milking J, et al. Cervicovaginal bacterial communities in reproductive-aged Tanzanian women with Schistosoma mansoni, Schistosoma haematobium, or without schistosome infection. ISME J 2021; 15:1539–50.
12. Gadoth A, Mvumbi G, Hoff NA, et al. Urogenital schistosomiasis and sexually transmitted infections among pregnant women in a schistosome-endemic region of the Democratic Republic of Congo. Am J Trop Med Hyg 2019; 101:288–36.
13. Leutcher PD, Ramaroson CE, Hoffmann S, et al. Coexistence of urogenital schistosomiasis and sexually transmitted infection in men and women living in an area where Schistosoma haematobium is endemic. Clin Infect Dis 2008; 47:775–82.
14. Yirenca-Tawiah D, Annang TN, Apea-Kubi KA, et al. Chlamydia trachomatis and Neisseria gonorrhoeae prevalence among women of reproductive age living in urogenital schistosomiasis endemic area in Ghana. BMC Res Notes 2014; 7:85–91.
40. Wall KM, Kilembe W, Vwalika B, et al. Schistosomiasis is associated with incident HIV transmission and death in Zambia. PLoS Negl Trop Dis 2018; 12:e0006902.
41. Mavedzenge SN, Pol BV, Cheng H, et al. Epidemiological synergy of Trichomonas vaginalis and HIV in Zimbabwean and South African women. Sex Transm Dis 2010; 37:460–6.
42. Masha SC, Coobs P, Sanders EJ, et al. Trichomonas vaginalis and HIV infection acquisition: a systematic review and meta-analysis. Sex Transm Infect 2019; 95:36–42.
43. Bocner AE, Baeten JM, Secor WE, et al. Associations between schistosomiasis and HIV-1 acquisition risk in four prospective cohorts: a nested case-control analysis. J Int AIDS Soc 2020; 23:e25534.
44. Wang CC, McClelland RS, Reilly M, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis 2001; 183:1017–22.
45. Kissinger P, Amenee A, Clark RA, et al. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis 2009; 36:11–6.
46. Anderson BL, Firthaber C, Liu T, et al. Effect of trichomoniasis therapy on genital HIV viral burden among African women. Sex Transm Dis 2012; 39:638–42.
47. Masese LN, Graham SM, Gitau R, et al. A prospective study of vaginal trichomoniaisis and HIV-1 shedding in women on antiretroviral therapy. BMC Infect Dis 2011; 11:13–6.
48. Guenther PC, Secor WE, Dezzutti CS. Trichomonas vaginalis-induced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1. Infect Immun 2005; 73:i155–60.
49. Kissinger P. Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues. BMC Infect Dis 2015; 15:1–8.
50. Thurman AR, Doncel GF. Innate immunity and inflammatory response to Trichomonas vaginalis and bacterial vaginosis: relationship to HIV acquisition. Am J Reprod Immunol 2011; 65:89–98.
51. Mercer E, Diala FG, Chen YP, et al. Leukocyte lysis and cytokine induction by the human sexually transmitted parasite Trichomonas vaginalis. PLoS Negl Trop Dis 2016; 10:e0004913.
52. Fichorova RN, Buck OR, Yamamoto HS, et al. The villain team-up or how Trichomonas vaginalis and bacterial vaginosis alter innate immunity in concert. Sex Transm Infect 2013; 89:460–6.
53. Cortes-Selva D, Fairfax K. Schistosome and intestinal helminth modulation of macrophage immunometabolism. Immunology 2021; 162:123–34.
54. Han IH, Song HO, Ryu JS. IL-6 produced by prostate epithelial cells stimulated with Trichomonas vaginalis promotes proliferation of prostate cancer cells by inducing M2 polarization of THP-1-derived macrophages. PLoS Negl Trop Dis 2020; 14:e0008126.
55. Hsieh YI, Fu CL, Hsieh MH. Helminth-induced interleukin-4 abrogates invariant natural killer T cell activation-associated clearance of bacterial infection. Infect Immun 2014; 82:2087–97.
56. Cherpes TL, Hillier SL, Meyn LA, et al. A delicate balance: risk factors for acquisition of bacterial vaginosis include sexual activity, absence of hydrogen peroxide-producing lactobacilli, black race, and positive herpes simplex virus type 2 serology. Sex Transm Dis 2008; 35:78–83.
57. Low N, Chersich MF, Schmidlin K, et al. Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. PLoS Med 2011; 8:e1000416.